Ten years after the original discovery of this potent molecule, VEGF still holds great therapeutic promise. But who said that it would be easy? Lee, R.J. et al. VEGF gene delivery to myocardium ...

In this review, we discuss the novel function and molecular mechanism of the VEGF-C/VEGFR-3 axis in cancer progression. Tumour invasion and metastasis are the critical steps in determining the ...

Experts said a certain type of bispecific antibody seems to have hit upon a crucial combination of two cancer targets: the proteins VEGF and either PD-1 or PD-L1. “It’s exactly that,” said ...

Opthea's lead compound, sozinibercept, targets VEGF-C/D and is in Phase 3 trials for wet AMD. Read more to see why I'm ...

In a new study, researchers have unveiled a surprising potential hero in the battle against hair loss: 2-deoxy-D-ribose, a simple sugar molecule that ... growth factor (VEGF), stimulating the ...

For example, the FDA-approved aptamer drug Pegaptanib (Macugen) targets vascular endothelial growth factor (VEGF) for the treatment of age-related macular degeneration ... Aptamers can be labeled with ...

Ivonescimab, a PD-1 x VEGF antibody from Summit Therapeutics, recently outperformed pembrolizumab in a head-to-head lung cancer clinical trials. NY-500 has a differentiated molecular design ...

Understanding the molecular biology of melanoma and unraveling of several signaling pathways over the last few years, as well as advances in immunology have led to the development of a number of ...

4D Molecular (FDMT) Therapeutics announced the ... a recombinant protein that inhibits VEGF-A, VEGF-B and PlGF, and a microRNA sequence that inhibits expression of VEGF-C. The data showed that ...

LM-299 has a differentiated molecular design, comprising an anti-VEGF antibody linked to two C-terminal single domain anti-PD-1 antibodies. A Phase 1 clinical trial for LM-299 is currently ...